Covea Finance 13F: New $7.8M Stake in VRTX
Key Points
- Covea Finance opened a new stake in Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX) by acquiring 15,000 shares valued at about $7.84 million.
- Vertex reported trailing twelve-month revenue of $12.59 billion and earnings of $17.27 per share, with its next earnings report scheduled for November 2, 2026.
- Other major institutional investors adjusted their holdings during the period, while Wall Street analysts maintain a consensus buy rating on the stock.
Get Vertex Pharmaceuticals Incorporated text alerts
We text you when insiders, Congress, analysts or big funds move on $VRTX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Vertex Pharmaceuticals Incorporated alert may contain errors. Disclosures
Covea Finance opened a new position in Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX), acquiring 15,000 shares valued at about $7.84 million. The investment firm revealed the new holding in a Form 13F filing with the U.S. Securities and Exchange Commission on October 21, 2026. Vertex closed at $524.52 on the day of the filing.
VRTX
Vertex Pharmaceuticals Incorporated
Covea Finance vs. the S&P 500
Hypothetical returns from Covea Finance's disclosed trades, not real profit or advice. How we model this.
What Changed in Covea Finance's Vertex Pharmaceuticals Position
Covea Finance established a fresh stake in the biotechnology company, starting the period with zero shares and ending with 15,000 shares. The reported value of the newly initiated position stood at $7,842,150 based on SEC filing data.
Other Institutional Activity in Vertex Pharmaceuticals
Other large investment managers also adjusted their holdings in the biotechnology firm during recent filing periods. Assenagon Asset Management S.A. grew its holdings by 459,747 shares, ending with 1,219,311 shares worth about $637.47 million. Livforsakringsbolaget Skandia, Omsesidigt lifted its stake by 21,920 shares to finish with 27,700 shares valued at roughly $14.48 million. Meanwhile, Capital International Investors trimmed its position by 431,119 shares, leaving it with 4,695,144 shares worth about $2.49 billion.
Vertex Pharmaceuticals Incorporated Stock Up 1.2%
The shares recently traded around $530.98 as of October 22, 2026, sitting above the $524.52 close recorded on the filing date. The stock has traded between a 52-week low of $403.16 and a 52-week high of $560.25.
Recent Earnings
Vertex generated trailing twelve-month revenue of $12.58 billion and basic earnings of $17.27 per share. The biotechnology firm operates with a net margin of 35.0% and a return on equity of 23.5%. The company's next quarterly earnings release is scheduled for November 2, 2026.
Dividend
Vertex Pharmaceuticals does not pay a dividend, retaining its earnings to fund research and development for specialty medicines.
Insider Buying and Selling at Vertex Pharmaceuticals Incorporated
Company insiders completed several transactions prior to the filing. Officer Carmen Bozic sold 596 shares on June 26, 2026, at an average price of $482.50 for a total of $287,570. Officer Joy Liu sold 828 shares on July 1, 2026, at $502.71 per share totaling $416,244. Officer Duncan J. Mckechnie sold 1,541 shares on July 2, 2026, at $519.00 each for $799,779, and Officer Ourania Tatsis sold 1,500 shares on the same day at $524.99 per share totaling $787,485.
Analysts Set New Price Targets
Wall Street research firms updated their views on the stock ahead of the filing. TD Cowen maintained its buy rating on August 4, 2026, raising its price target to $550.00 from $525.00. Truist Securities maintained a buy rating on August 5, 2026, lifting its target to $565.00 from $560.00. Barclays maintained an overweight rating on August 5, 2026, moving its target to $617.00 from $615.00. UBS maintained a buy rating on September 28, 2026, adjusting its target from $585.00 to $615.00. RBC Capital maintained an outperform rating on October 8, 2026, raising its target to $576.00 from $570.00. The stock carries a consensus buy recommendation with a mean price target of $571.46 across 28 analyst opinions.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a Boston-based biotechnology company that researches and develops transformative medicines for serious human illnesses. The firm focuses on specialty pharmaceutical markets, creating treatments for conditions such as cystic fibrosis, sickle cell disease, transfusion dependent beta thalassemia, and acute pain.
Bottom Line
Covea Finance's new investment highlights institutional interest in the biotechnology firm as it approaches its next financial report on November 2, 2026. Investors will monitor upcoming earnings results and subsequent regulatory filings for further shifts in institutional ownership.
Related Filing Alerts
Source: Covea Finance's 13F filing on $VRTX (Oct 21, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts